Needham analyst Mike Matson lowered the firm’s price target on Haemonetics (HAE) to $68 from $84 and keeps a Buy rating on the shares. The company’s Q1 topped estimates but it maintained prior guidance despite the beat, the analyst tells investors in a research note. The firm says the the stock is trading down 21% given deterioration in Haemonetics’ Interventional Technologies business.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics backs FY26 adjusted EPS view $4.70-$5.10, consensus $4.87
- Haemonetics reports Q1 EPS $1.10, consensus $1.02
- HAE Upcoming Earnings Report: What to Expect?
- Haemonetics Holds Successful Annual Shareholders Meeting
- Haemonetics Receives Buy Rating Amid Strategic Positioning and Positive Long-term Outlook